Diamyd Medical
9.70 SEK
+1.15 %
Less than 1K followers
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
+1.15 %
-3.00 %
-14.01 %
-5.83 %
-40.72 %
-36.72 %
-36.83 %
-67.75 %
+223.04 %
Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.
Read moreMarket cap
1.33B SEK
Turnover
3.61M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28.1
2026
Interim report Q1'26
25.3
2026
Interim report Q2'26
24.6
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
Bulletin from Annual General Meeting of Diamyd Medical AB
Diamyd Medical AB: Annual Report 2024/2025
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools